Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: The invention provides TRF1 inhibitors and compositions comprising them for the treatment of a brain cancer, such as a glioblastoma, and particularly a glioblastoma multiforme (GBM). PI3K inhibitors can be among the TRF1 inhibitors used. The compositions can comprise more than one TRF1 inhibitor, being particularly advantageous that at least one of the inhibitors is a PI3K inhibitor and that at least a second possible TRF1 inhibitor present is selected from the group an RTK inhibitor, a MEK inhibitor, an ERK inhibitor, an HSP90 inhibitor, docetaxel and gemcitabine, because such compositions show a synergic effect. The invention also relates to a method for identifying compounds candidates to be used for treating glioblastoma or other cancers, which method is based on the identification of the compound as a TRF1 inhibitor.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: The invention relates to methods and reagents for the determination of telomere length in tissue sections by the single cell telomeric mapping technique based on a fluorescent in situ hybridization step using a telomere-specific probe and an interpolation step using a standard curve correlating fluorescent intensity and telomere length obtained from a collection of cell lines of known telomere length. The invention further relates to methods for the identification of stem cell niches within tissues and for the identification of compounds capable of triggering stem cell mobilization using the telomere length as criteria for the identification of stem cells and which rely on the single cell telomeric mapping technique of the invention.

Abstract: The invention relates to methods and reagents for the determination of telomere length in tissue sections by the single cell telomeric mapping technique based on a fluorescent in situ hybridization step using a telomere-specific probe and an interpolation step using a standard curve correlating fluorescent intensity and telomere length obtained from a collection of cell lines of known telomere length. The invention further relates to methods for the identification of stem cell niches within tissues and for the identification of compounds capable of triggering stem cell mobilization using the telomere length as criteria for the identification of stem cells and which rely on the single cell telomeric mapping technique of the invention.

Abstract: Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

Abstract: Nucleic acids comprising the RNA component of a mouse, rat, Chinese hamster and bovine telomerase are disclosed, as are recombinant expression plasmids comprising said nucleic acids and host cells transformed with said recombinant expression plasmids.